These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8452114)

  • 81. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
    Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients.
    Dogliotti L; Antonacci RA; Pazè E; Ortega C; Berruti A; Faggiuolo R
    Drugs; 1992; 43 Suppl 3():6-10. PubMed ID: 1380432
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial.
    Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tamura T; Fujiwara Y; Mae M; Fukuda M; Ohe Y; Sasaki S
    Jpn J Clin Oncol; 1989 Mar; 19(1):40-4. PubMed ID: 2921817
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
    Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
    Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
    Dix S; Cord M; Howard S; Coon J; Belt R; Geller R
    Bone Marrow Transplant; 1999 Sep; 24(5):561-6. PubMed ID: 10482943
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
    Depierre A
    Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Treatment of nausea and vomiting induced by a 24-hour i.v. infusion of cisplatin].
    Nagai H; Suga S; Horiuchi Y; Kyokane K; Miwa Y; Aoki Y; Yasue K; Noro T; Kamikawa R; Ninomiya E
    Gan No Rinsho; 1990 Jun; 36(7):791-6. PubMed ID: 2113110
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind study.
    Molino A; Guglielmo L; Azzolini ME; Biondani P; Capelli MC; Grandinetti A; Griso C; Martinelli G; Martini N; Zanotti R
    Oncology; 1991; 48(2):111-5. PubMed ID: 1997932
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.
    Warrington PS; Allan SG; Cornbleet MA; MacPherson JS; Smyth JF; Leonard RC
    Br Med J (Clin Res Ed); 1986 Nov; 293(6558):1334-7. PubMed ID: 3790968
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Randomized crossover comparison of high-dose intravenous metoclopramide versus a five-drug antiemetic regimen.
    Plezia PM; Alberts DS; Kessler JF; Berens PL; Chase JL; Roe DJ
    J Pain Symptom Manage; 1990 Apr; 5(2):101-8. PubMed ID: 2189929
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
    Markman MR; Peterson G; Kulp B; Markman M
    Gynecol Oncol; 2002 Jun; 85(3):435-7. PubMed ID: 12051870
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy.
    Basurto C; Roila F; Del Favero A; Ballatori E; Minotti V; Tonato M
    Cancer Invest; 1988; 6(5):475-9. PubMed ID: 3063335
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients.
    Sorbe B; Hallén C
    Eur J Gynaecol Oncol; 1991; 12(1):31-7. PubMed ID: 2050157
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Antiemetic activity of oral lorazepam in addition to methylprednisolone and metoclopramide in the prophylactic treatment of vomiting induced by cisplatin. A double-blind, placebo-controlled study with crossover design.
    Clerico M; Bertetto O; Morandini MP; Cardinali C; Giaccone G
    Tumori; 1993 Apr; 79(2):119-22. PubMed ID: 8346563
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy.
    Rusthoven J; Pater J; Kaizer L; Wilson K; Osoba D; Latreille J; Findlay B; Lofters WS; Warr D; Laberge F
    Ann Oncol; 1991 Oct; 2(9):681-6. PubMed ID: 1742224
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial.
    Bécouarn Y; Nguyen BB; David M; Lakdja F; Brunet R; Chauvergne J
    Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1421-4. PubMed ID: 3595666
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Control of cisplatin induced emesis--a multidisciplinary intervention strategy.
    Fürst CJ; Johansson S; Fredrikson M; Hursti T; Steineck G; Peterson C
    Med Oncol Tumor Pharmacother; 1992; 9(2):81-6. PubMed ID: 1341720
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Intravenous itasetron: establishing the effective dose range for the prophylactic control of acute emesis in cancer patients undergoing high-dose cisplatin chemotherapy.
    Patoia L; Del Favero A; Giglietti A; Malacarne P; Donati D; Indelli M; Bensi G; Palladino MA; Cigarini P; Kempe R; Voigt T
    Clin Oncol (R Coll Radiol); 1999; 11(2):99-104. PubMed ID: 10378635
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study.
    Tomirotti M; Dimaiuta M; Confalonieri M; Scanni A
    Support Care Cancer; 1994 Nov; 2(6):389-92. PubMed ID: 7858933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.